Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Osteoarthritis of the knee or hip confirmed by X-ray~* Documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, NSAIDs and either tramadol or opioids~* Meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline~* Willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol~* Women able to have children must agree to use 2 forms of contraception during the study~Exclusion Criteria:~* Body Mass Index (BMI) greater than 39~* History of diseases other than osteoarthritis in a shoulder, hip or knee (example, rheumatoid arthritis, gout, joint infections, osteonecrosis)~* Patients with x-ray showing joint conditions such as osteonecrosis (dead bone) or certain types of fractures~* Patients who have had significant trauma or surgery to a knee, hip or shoulder within the previous year~* Planned surgical procedure during the study~* Patients who are largely or wholly incapacitated (example bedridden or confined to a wheelchair, permitting little or no self-care)~* Patients who would be unwilling or unable to undergo joint replacement surgery if one eventually became necessary~* Patients with significant conditions other than osteoarthritis that could interfere with assessment of pain in the joints (example fibromyalgia, lupus erythematosus)~* Patients with significant heart, neurological or psychiatric diseases~* Patients who had cancer other than certain skin cancers within the past 5 years~* Patients with alcohol, analgesic (pain medications) or drug abuse within the past 2 years~* Women who are pregnant, breast-feeding or intending to become pregnant or breast-feed during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo administered subcutaneously at day 0 and week 8
- Tanezumab 2.5 mg (Type: EXPERIMENTAL): tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
- Tanezumab 2.5mg/5mg (Type: EXPERIMENTAL): tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8

Based on this trial design, predict the completion outcome and termination type (if applicable).